William Blair Investment Management LLC Acquires 1,107,083 Shares of Amicus Therapeutics, Inc. $FOLD

William Blair Investment Management LLC increased its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 7.6% in the third quarter, HoldingsChannel reports. The institutional investor owned 15,749,240 shares of the biopharmaceutical company’s stock after purchasing an additional 1,107,083 shares during the quarter. William Blair Investment Management LLC owned 0.05% of Amicus Therapeutics worth $124,104,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. R Squared Ltd grew its holdings in Amicus Therapeutics by 82.0% during the 3rd quarter. R Squared Ltd now owns 25,824 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 11,636 shares during the period. DNB Asset Management AS grew its stake in shares of Amicus Therapeutics by 17.6% during the third quarter. DNB Asset Management AS now owns 46,161 shares of the biopharmaceutical company’s stock worth $364,000 after purchasing an additional 6,920 shares during the period. Choreo LLC increased its holdings in Amicus Therapeutics by 41.0% in the third quarter. Choreo LLC now owns 22,656 shares of the biopharmaceutical company’s stock valued at $179,000 after purchasing an additional 6,586 shares during the last quarter. Fox Run Management L.L.C. acquired a new position in Amicus Therapeutics in the third quarter valued at about $553,000. Finally, EverSource Wealth Advisors LLC boosted its holdings in Amicus Therapeutics by 86.7% during the third quarter. EverSource Wealth Advisors LLC now owns 8,316 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 3,861 shares during the last quarter.

Insider Activity

In related news, insider David Michael Clark sold 25,643 shares of the stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $11.00, for a total transaction of $282,073.00. Following the completion of the transaction, the insider directly owned 271,332 shares in the company, valued at approximately $2,984,652. This trade represents a 8.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bradley L. Campbell sold 77,926 shares of Amicus Therapeutics stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $10.86, for a total value of $846,276.36. Following the completion of the sale, the chief executive officer directly owned 1,129,782 shares in the company, valued at approximately $12,269,432.52. This represents a 6.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 218,798 shares of company stock valued at $2,710,962 over the last ninety days. 2.20% of the stock is owned by insiders.

Amicus Therapeutics Stock Performance

Shares of FOLD opened at $14.37 on Friday. The firm has a market cap of $4.51 billion, a P/E ratio of -179.63 and a beta of 0.38. Amicus Therapeutics, Inc. has a twelve month low of $5.51 and a twelve month high of $14.38. The company has a debt-to-equity ratio of 1.43, a quick ratio of 2.09 and a current ratio of 2.84. The firm’s 50 day moving average price is $14.29 and its two-hundred day moving average price is $10.68.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.03). The company had revenue of $185.21 million for the quarter, compared to the consensus estimate of $185.00 million. Amicus Therapeutics had a positive return on equity of 4.15% and a negative net margin of 4.27%.The firm’s revenue was up 23.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.09 EPS. On average, analysts forecast that Amicus Therapeutics, Inc. will post 0.15 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on FOLD shares. Needham & Company LLC downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 19th. TD Cowen downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 target price for the company. in a research note on Monday, December 22nd. Zacks Research cut shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 26th. Leerink Partners lowered shares of Amicus Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $17.00 to $14.50 in a report on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Three analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Amicus Therapeutics presently has an average rating of “Hold” and an average target price of $15.39.

Amicus Therapeutics Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.